Navigation Links
QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
Date:5/1/2008

EDMONTON, May 1 /PRNewswire/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.

Graeme Macaloney PhD, PEng, Founder, President & CEO of QSV said: "We are extremely pleased and honoured that Pfizer has chosen QSV Biologics from a strong field of contending CMOs as their manufacturing partner for this project. The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV's continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer."

"Pfizer is pleased to engage QSV for the clinical manufacturing of a complex biotechnology product," said Rick Rutter, Ph.D., Vice President of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global Research and Development. "Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer's vision of becoming a top tier biotherapeutic company."

QSV Biologics, Ltd. (http://www.qsvbiologics.com), is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV's facility has a 12 yr track record including an Establishment License for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan "Customer Value Enhancement Award" in 2005 and the BioAlberta "Company of the Year Award" in 2007. QSV's global clientele spans 3 continents and develops protein therapeutics, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value.


'/>"/>
SOURCE QSV Biologics, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... AURORA, Colo (PRWEB) , ... January 12, 2017 ... ... and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a ... eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased ...
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, Poultry, ... to 2022", published by MarketsandMarkets, the global market is estimated to be valued ... by 2022, at a CAGR of 6.96% from 2016. ... ... ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... clinics in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand ... path of discovery. , Now, as an assistant professor of biology and biotechnology ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):